Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

Abstract: A formulation for treating a patient with hepatocellular carcinoma is disclosed. The formulation comprises therapeutic agents in the form of nanoparticles containing one or more proteins or polysaccharides. The therapeutic agent is conjugated to an active targeting agent causing the formulation to preferentially segregate to the hepatocellular carcinoma tissue to release the therapeutic agents. Methods of treating hepatocellular carcinoma using the formulations are also disclosed.

Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.

Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.

Abstract: A series of natural products including phyllanthusum, an arylnaphthalene lignan derivative, with anticancer and antitumor and immunostimulating activity are disclosed. The invention further encompasses methods of adding water solubilizing groups to the arylrings that include phosphonyl groups.

Abstract: Described herein, inter alia, are macrocyclic lactones such as ivermectin and methods for their use in treating, for example, hyperproliferative disorders such as cancer.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises an inhibitor of the eIF4E gene product and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides for the use of a combination therapy for treating patients having a neoplasm, a proliferative disorder, pre-neoplasm or a precancerous lesion, comprising an inhibitor of the eIF4E gene product, a chemotherapeutic agent, and a therapeutically effective amount of a hedgehog pathway inhibitor; and the method of using said combination therapy.

Abstract: Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

Abstract: An adhesive and solid particulates adhered to the pads of an animal's paw, the adhesive being cured, thereby increasing the friction of the surface of the pads; and a method of increasing the friction of an animal's paw by applying to clean, dry pads of the animal's paw a layer of uncured adhesive, and while the adhesive layer is uncured, contacting the paw with particulates to adhere the particulates to the pad, then curing the adhesive.

Abstract: The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectable microparticle according to claim 1 wherein the polyesteramide co-polymer further comprises a diacid, a diol different from bicyclic-1,4:3,6-dianhydrohexitol and at least two different amino-acids. The formulation is used to treat pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the formulation once or twice a year.

Abstract: Described herein is a method of preparing a hybrid hydrogel paramagnetic nanoparticle. In certain embodiments, the hybrid hydrogel paramagnetic nanoparticle comprises a therapeutic agent. In certain embodiments, the nanoparticle contains alcohol. In certain embodiments, the nanoparticles incorporate fatty acids. Also described herein, is a method of preparing a hybrid hydrogel NO-releasing nanoparticle. In another embodiment, provided herein is a method of preparing a S-nitrosocaptopril hydrogel nanoparticle. Also described herein is a method of preparing a curcumin-based hydrogel nanoparticle. Further, described herein is a method for treating a bacterial infection in a burn wound using curcumin-based hydrogel nanoparticles. Also provided herein is a method of treating a fungal infection using photoactivated curcumin-based hydrogel nanoparticles. In certain embodiments, the fungal infection is caused by dermatophytic fungi.

Abstract: The present invention relates to a calcium carbonate composition for ameliorating, preventing and treating osteoporosis, and a manufacturing method therefor. More specifically, the present invention relates to a calcium carbonate composition for alleviating, preventing and treating osteoporosis, the composition comprising calcium, magnesium and zinc, and having calcium carbonate microparticles formed by the supply of carbon dioxide gas. The present invention provides a composition for maximizing the absorption of calcium, the composition being developed as a health food, food material or the like, and displaying the effects of relieving and alleviating illnesses and symptoms caused by a lack of calcium.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval —administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.

Abstract: The invention described herein is directed to copper-containing compounds for the treatment of toxin exposure (including pore-forming toxin exposure) in a subject in need thereof. The invention is further directed to methods of treating toxin exposure in a subject in need thereof.

Abstract: The present invention provided an anticancer nano-silver composition for the treatment of lung cancer. The composition contains spherical nano-silver powder 12-200 mg/kg, pharmaceutically acceptable dispersing agent carbomer 700-800 mg/kg, triethanolamine 700-800 mg/kg, glucose 2.8-3.2 g/kg, and purified water as the diluent; of the spherical nano-silver powder, the purity of silver is ?99.99% and the particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit proliferation of the human non-small cell lung cancer A549, and cause all cells death. The nano-silver composition of the present invention can be used in the manufacture of medicaments and for the treatment of lung cancer.

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Abstract: Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.

Abstract: The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.

Abstract: The embodiments of the present invention provide a method for the treatment of glioblastoma using Wharton Jelly-mesenehmal stem cells (WJ-MSC) derived from human umbilical cord. The mesenchymal stem cells have potential to inhibit the glioblastoma cancer cells. For isolating the MSC, the donor is screened for infectious diseases. The consent from the donor is taken for the collection of the umbilical cord sample. The MSC are mechanically harvested or isolated from the Wharton's jelly of umbilical cord. The WJ-MSC are cultured and propagated in vitro and harvested. The harvested WJ-MSC is subjected for characterization. The characterized WJ-MSC's are cryo-preserved. The tumors which do not respond to temozolomide (TMZ) respond to WJ-MSC. WJ-MSC does not exert any toxic effect on any human organ. WJ-MSC are cryoprotective to healthy cells and cytotoxic to glioblastoma cells.

Abstract: The present invention provides a bone formation promoter having high biological safety and capable of promoting bone formation. The bone formation promoter of the present invention includes a self-assembling peptide capable of forming a ?-sheet structure in an aqueous solution having a neutral pH; and a bone chip. A sum of charges of amino acid residues constituting the self-assembling peptide at pH 7.0 is unequal to 0.

Abstract: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.

Abstract: This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium, a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)? and peroxisome proliferator activated receptor (PPAR)?; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver.

Abstract: The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF).

Abstract: Described herein is an adenovirus comprising an AB-loop comprising a targeting motif and methods of making and using the adenovirus. The targeting motif of the adenovirus can selectively bind to a tumor cell. The targeting motif of the adenovirus can selectively bind to cell markers and/or cell surface antigens including, for example, CD 133.

Abstract: The present invention relates to microorganism biomass and a feed or food composition comprising said biomass for use in preventing or reducing the adverse effects of pathogens in animal or human digestive tract.

Abstract: A novel treatment for topical inflammatory conditions such as acne, eczema, shingles, insect bites, and hives is provided, consisting of the application of a herbal cream or ointment which incorporates grounded PawPaw Seeds in a granular form. The cream preferably contains one or more thickeners, a bio-adhesive agent such as petroleum jelly such that the cream can stick to the area to be treated.

Abstract: This invention relates to the field of cancer management, and in particular to the field of phytomedicine and nutraceutical composition for management of cancer, control of viral, bacterial and fungal infections, as well as other associated illnesses. This invention also pertains to the method of controlled, ecologically self-sustainable continuous horticulture combined with aquaculture (aquaponics system), for the described herbal plants and to the method for manufacturing the end products, both methods as per applicable ISO 14698 series and ISO-14644 series standards, EU GMP annex 1 and pharmacological Good Manufacturing Practice. The present application focuses primarily on Acanthospermum hispidum DC and on Solidago Canadensis L.

Abstract: Methods of treating adult non-human animals afflicted with diarrhea, particularly, stress-induced diarrhea, by administering to an animal in need thereof an effective amount of a pharmaceutical formulation of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. are provided. In particular, the adult animals include horses and camels which frequently suffer from stress-induced diarrhea and its symptoms, and the administered proanthocyanidin polymer composition is isolated from a Croton lechleri. The composition, which can be enteric or non-enteric, is administered particularly to target the intestine/gut of the animal via a mode and under conditions conducive and sufficient for providing effective treatment of diarrhea in the affected animal. Preferred modes of administration include orally providing an effective concentration of the proanthocyanidin polymer composition, e.g., via an oral paste formulation, drench, animal feed, or water bottle, to the affected animal.

Abstract: A method of obtaining one or more fractions from a plant material of Withania somnifera (WS) is disclosed. The method includes subjecting the plant material to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain at least one extract. The method further includes subjecting the at least one extract obtained from the hydro-alcoholic extraction to at least one of de-pigmentation, de-fatting and detoxification process to obtain the one or more fractions. The one or more fractions thus obtained contain Withaferin A in a concentration greater than concentrations of other pharmacologically active ingredients present in the one or more fractions. The one or more fraction thus obtained and one or more compositions containing the one or more fractions are effective in inhibiting proliferation of mammalian cancerous cells.

Abstract: Methods of making liquid compositions that can be used, for example, to improve human health, and in particular brain health are provided. The L-Theanine is solubilized in water prior to the addition of other ingredients, such as Acetyl-L-Carnitine, Choline bitartrate, Inositol, N-Acetyl L-Tyrosine and pyrroloquinoline quinone (PQQ). In some embodiments, additional ingredients such as DMAE bitartrate, Vitamin D, Niacin, Vitamin B6, Vitamin B12, Vitamin E and Green Tea Extract are added. In addition, in some embodiments, natural flavors and natural sweeteners are added. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health.

Abstract: Use of dietary fibre material extracted from grasses of the Poaceae family such as sugarcane, sweet sorghum and bamboo for the alleviation of chronic inflammation through improvement in intestinal flora and reduction of pro-inflammatory pathways.

Abstract: Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt, which is prepared by firstly heat-treating mineral rich solar salt and bamboo tree at a high temperature, that is, 1,100° C. or more; and two or more time repeating the heat-treating of the first heat-treated salt and bamboo tree under the above-described conditions, includes a large amount of hydrogen sulfide-producing material and has a purple color, and when the heat-treated salt is used along with aspirin, the heat-treated salt has an excellent effect on preventing stomach damage, thereby significantly reducing bleeding, ulcer, and the damage of mucous membrane, induced by aspirin.

Abstract: The present invention relates to a method for preparing a garlic-fermented composition and a garlic-fermented composition prepared by the method, and the purpose of the present invention is to provide a garlic-fermented composition which is easy to take, has no side effect, and improves excellent pharmacological and physiological efficacies of garlic. To achieve this, the method for preparing a garlic-fermented composition according to an aspect of the present invention, comprises: a first fermentation step of mixing garlic, water, and a ferment strain, followed by fermentation, thereby decomposing and converting sugars and proteins of the garlic; and a second fermentation step of additionally supplying a carbon source to a filtrate obtained through solid-liquid separation of the fermented product, followed by fermentation, thereby removing ammonia of the filtrate and decomposing and converting the additionally supplied carbon source.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: The present invention provides compounds of Formula I and Formula II and related compositions and methods.

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.

Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).

Abstract: The object of the present invention is to provide a hemostatic pharmaceutical composition that has higher usability compared to a hemostatic agent employing conventional biogels and may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a hemostatic pharmaceutical composition comprising a sugar chain-polypeptide complex characterized in that said polypeptide in said sugar chain-polypeptide complex is a polypeptide comprising an amino acid sequence in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide.

Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotrauniatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.

Abstract: The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.

Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.

Abstract: The present invention provides a composition comprising cells obtainable by bone marrow aspiration, or multipotent or pluripotent progenitor cells, and granulocyte-colony stimulating factor (G-CSF), as a combined preparation for simultaneous, separate or sequential use in the therapy of cardiomyopathy in a subject, wherein the cells are administered directly to the myocardium of the subject.

Abstract: A method of ameliorating, inhibiting, preventing, or reducing male infertility in a subject undergoing or in need of chemotherapy by administering to the subject a granulocyte colony-stimulating factor in a protective amount, prior to, during or after administration of one or more chemotherapeutic agents to the subject.

Abstract: The invention relates to the stimulation of appetite and treatment of such appetite-suppressed conditions as cachexia, and in particular to an intranasal route of administration for appetite-stimulating agents such as peptide compounds and fragments related to or comprising the Agouti-Related Peptide (AgRP).